Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-02
2007-10-02
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S399000, C424S009100, C424S551000, C435S325000, C435S069100, C536S023500
Reexamination Certificate
active
11209542
ABSTRACT:
The present invention provides methods of treating pathologic conditions associated with intestinal ischemia. In the methods, patients at risk for or suffering from intestinal ischemia are treated with a heparin-binding epidermal growth factor product.
REFERENCES:
patent: 5057494 (1991-10-01), Sheffield
patent: 5811393 (1998-09-01), Klagsbrun et al.
patent: 6191109 (2001-02-01), Besner et al.
patent: 6387878 (2002-05-01), Besner et al.
patent: WO 92/06705 (1992-04-01), None
Feng et al., J. Ped. Surg. 41, 144-149 (Jan. 2006).
Barnard et al., “Epidermal Growth Factor-Relat ed Peptides and Their Relevance to Gastrointestinal Pathophysiology,”Gastroenterology, 108:564-580 (1995).
Bell et al., “The Micro bial Flora and Antimicrobial Therapy of Neonatal Peritonitis,”J. Ped. Surg.,15:569 (1980).
Besner et al., “Isolation and Characterization of a Macrophage-Derived Heparin-Bbinding Growth Factor,”Cell Regulation, 1:811-819 (1990).
Besner et al., “Interaction of Heparin-Binding E GF-Like Growth Factor (HB-EGF) with the Epidermal Growth Factor Receptor: Modulation by Heparin, Heparinase, or Synthetic Heparin-Binding HB-EGF Fragments,”Growth Factors, 7:289-296 (1992).
Carey et al., “Molecula r Cloning and Characterization of N-Syndecan, a Novel Transmembrane Heparan Sulfate Proteoglycan,”J. Cell. Biol., 117(1):191-201 (1992).
Dignass and Podolsky, “Cytokine Modulat ion of Intestinal Epithelial Cell Resitution: Cental Role of Transforming Growth Factor β,”.
Higashiyama et al., “A Heparin-Binding Growth Factor Secreted by Macrophage-like Cells That Is Related to EGF,”Science. 251:936-939 (1991).
Miyazaki et al., “Oxidative Stress Increases G ene Expression of Heparin-Binding EGF-like Growth Factor and Amphiregulin in Cultured Rat Gastric Epithelial Cells,”Biochem. Biophys. Res. Comm., 226:542-546 (1996).
Parks et al., “Contributi ons of Ischemia and Reperfusion to Mucosal Lesion Formation,”Am. J. Physiol., 250:G749-753 (1986).
Prigent and Lemoine, “The Type 1 (EGFR-Related) Family of Growth Factor Receptors and Their Ligands,”Prog. Growth Factor Res., 4:1-24 (1992).
Villa et al., “Epidermal Growth Factor Reduces Ischemia-Reperfusion Injury in Rat Small Intestine,”Gastroenterology, 110 (4Suppl.):A372 (1996).
Killion et al., “Exogenous Epidermal Growth Factor Fails To Accelerate Functional Recovery In The Autotransplanted Ischemic Pig Kidney,”The Journal of Urology, 150: 1551-1556,(Nov. 1993).
Galvão et al., “Epidermal Growth Factor (EGF) did not Protect against Renal Ischemia,”J. Am Soc. Nephrol., 7(9): 1824 (1996).
Robinson et al., “Epidermal Growth Factor (hEGF) Has No Effect On Murine Intestine Epithelial Damage And Regeneration After Melphalan,”Br. J. Cancer, 52:733-737 (1985).
Besner Gail E.
Pillai Srikumar B.
Children's Hospital, Inc.
Kam Chih-Min
Marshall & Gerstein & Borun LLP
LandOfFree
Methods of treating intestinal ischemia using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating intestinal ischemia using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating intestinal ischemia using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850177